Could fluvoxamine and metformin beat long COVID fatigue?

NCT ID NCT06128967

Completed Symptom relief Sponsor: Cardresearch Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase 3 trial tested whether two widely available drugs—fluvoxamine (an antidepressant) and metformin (a diabetes drug)—can reduce fatigue and other symptoms in people with long COVID. 399 adults with confirmed prior COVID-19 infection and persistent symptoms took part. The study compared these drugs against a placebo to see if they improve daily functioning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fluvoxamine and Metformin
What this could lead to: If successful, this could point toward a simple, affordable treatment to reduce fatigue and other long COVID symptoms.
What could go wrong: This trial is completed but results are not yet published. Even if positive, these drugs may not work for everyone with long COVID, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC FATIGUE SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 myalgic encephalomeyelitis/chronic fatigue syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC FATIGUE SYNDROME LONG COVID-19 SYNDROME

Contacts and locations

Locations

CARDRESEARCH - Cardiologia Assistencial e de Pesquisa

Belo Horizonte, Minas Gerais, 30150240, Brazil
City of Brumadinho

Brumadinho, Minas Gerais, 35.460-000, Brazil
City of Ibirité Public Health Authority

Ibirité, Minas Gerais, Brazil
Governador Valadares City Public Health Authority

Governador Valadares, Minas Gerais, Brazil
Sociedade Padrao de Educacao Superior

Montes Claros, Minas Gerais, Brazil
Universidade Federal de Ouro Preto

Ouro Preto, Minas Gerais, 35400000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.